Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 14/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.78 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.78 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.78 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.64 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.63 |
| ▸ | DRD2 | P14416 | 3/20 | 0.63 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5482985 | 0.99 | CHRM1 (0.76) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL4403937 | 0.92 | CHRM1 (0.70) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL44492 | 0.92 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL29467164 | 0.92 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL5386489 | 0.91 | CHRM1 (0.69) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL8863390 | 0.90 | CHRM1 (0.71) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL8863384 | 0.90 | CHRM1 (0.71) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| Hydrochloric Acid SCHEMBL7295362 | 0.90 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| Hydrochloric Acid SCHEMBL31285831 | 0.90 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| Ammonia Solution, Strong SCHEMBL1763968 | 0.90 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | claimed |
| WO-2010083129-A2 | IMPLANTABLE DELIVERY VEHICLE FOR OCULAR DELIVERY OF MUSCARINIC ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-22 | — | — | WO | disclosed |
| EP-1598339-B1 | 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-06-24 | — | — | EP | disclosed |
| US-7279490-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279490-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279490-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1515722-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050176765-A1 | Ophthalmic compositions for treating ocular hypertension | MSD K.K. (JP) | 2005-08-11 | — | — | US | disclosed |
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | disclosed |
| EP-1515722-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-1999032443-A1 | MUSCARINIC AGENTS AND USE THEREOF TO TREAT GLAUCOMA, MYOPIA, AND VARIOUS OTHER CONDITIONS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032479-A1 | PHTHALIMIDE-PIPERIDINE, -PYRROLIDINE AND -AZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MUSCARINIC RECEPTOR (ANT-)AGONISTS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032486-A1 | MUSCARINIC AGENTS AND USE THEREOF TO TREAT GLAUCOMA, MYOPIA AND VARIOUS OTHER CONDITIONS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032489-A1 | MUSCARINIC AGENTS AND USE THEREOF TO TREAT GLAUCOMA, MYOPIA AND VARIOUS OTHER CONDITIONS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5691323-A | BENZIMIDAZOL-2-ONES | MERCK & CO., INC. (US) | 1997-11-25 | — | — | US | disclosed |
| US-5691323-A | BENZIMIDAZOL-2-ONES | MERCK & CO., INC. (US) | 1997-11-25 | — | — | US | disclosed |
| US-5574044-A | BENZIMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF MYOPIA | MERCK & CO., INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5574044-A | BENZIMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF MYOPIA | MERCK & CO., INC. (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1996013262-A1 | MUSCARINE ANTAGONISTS | MERCK & CO., INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| WO-1996013262-A1 | MUSCARINE ANTAGONISTS | MERCK & CO., INC. (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | CHRM3, CYSLTR2, CHRM2 | CHRM1 18/4885CHRM2 3/4885CHRM4 23/4885 |
| US-20050176765-A1 | Ophthalmic compositions for treating ocular hypertension | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885CHRM2 2/4885CHRM4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.